BasilioColligris, Jesús Pintor
176
Vehicle on the Signs andSymptoms ofDryEye in theControlledAdverseEnvironment
(CAE)Model (abstract) 2012ARVOE-Abstract 577/A45.
56.
Belimumab.
ClinicalTrials.gov
Identifier:
NCT01160666
(2012).
57.
Cornec D, SarauxA, Devauchelle-Pensec V, et al. The future of B cell-targeted
therapies inSjogren's syndrome.
Immunotherapy.
5
(6), 639-46 (2013).
58.
Rituximab.
ClinicalTrials.gov
Identifier:
NCT00740948
.
(2013).
59.
Moerman RV, Arends S, Meiners PM, et al. EULAR Sjogren's Syndrome
DiseaseActivity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in
a randomised controlled trial.
AnnRheumDis.
73
(2), 472-4 (2014).
60.
Bartels PS. Use of loteprednol etabonate for the treatment of dry eye.
WO2005094836A2 (2005)
61.
Pavesio CE, Decory HH. Treatment of ocular inflammatory conditions with
loteprednol etabonate.
Br JOphthalmol.
92
(4), 455-9 (2008).
62.
Sheppard JD, Scoper SV, Samudre S. Topical loteprednol pretreatment reduces
cyclosporine stinging in chronic dry eye disease.
J Ocul Pharmacol Ther.
27
(1), 23-7
(2011).
63.
Wan PX, Wang XR, Song YY, et al. (Study on the treatment of dry eye with
Loteprednol Etabonate).
ZhonghuaYanKeZaZhi.
48
(2), 142-7 (2012).
64.
Ogawa T, Watanabe N, Okumura Y. Method for preventing or treating dry eye
or disease caused therefrom. US19985830913 (1998)
65.
Munakata W, Liu Q, Shimoyama T, et al. Ecabet sodium attenuates reactive
oxygen species produced by neutrophils after priming with bacterial
lipopolysaccharides.
Luminescence.
18
(6), 330-3 (2003).
66.
Shimoyama T, Fukuda Y, Fukuda S, et al. Ecabet sodium eradicates
Helicobacter pylori infection in gastric ulcer patients.
J Gastroenterol.
31 Suppl 9
59-
62 (1996).
67.
Zhang JZ, Cavet ME, VanderMeid KR, et al. BOL-303242-X, a novel selective
glucocorticoid receptor agonist, with full anti-inflammatory properties in human ocular
cells.
Mol Vis.
15
2606-16 (2009).
68.
Vollmer TR, Stockhausen A, Zhang JZ. Anti-inflammatory effects of
mapracorat, a novel selective glucocorticoid receptor agonist, is partially mediated by
MAP kinase phosphatase-1 (MKP-1).
JBiol Chem.
287
(42), 35212-21 (2012).
69.
Schoepe S, Schacke H, Bernd A, et al. Identification of novel in vitro test
systems for the determination of glucocorticoid receptor ligand-induced skin atrophy.
SkinPharmacol Physiol.
23
(3), 139-51 (2010).
70.
AL-43546.
ClinicalTrials.gov
Identifier:
NCT00760045
(2010).
71.
Caballero-Velazquez T, Sanchez-Abarca LI, Gutierrez-Cosio S, et al. The novel
combination of sirolimus and bortezomib prevents graft-versus-host disease but
maintains the graft-versus-leukemia effect after allogeneic transplantation.
Haematologica.
97
(9), 1329-37 (2012).
